Smart nanoparticles assembled by endogenous molecules for siRNA delivery and cancer therapy via CD44 and EGFR dual-targeting
Open accessAbstract
We developed an anticancer siRNA delivery system (named HLPR) through modular assembly of endogenous molecules. The structure of HLPR was a tightly condensed siRNA-peptide inner core in turn surrounded by the disordered lipid layer and thin HA coating from which the EGFR-targeted amino acid sequences of YHWYGYTPQNVI partially protrude outside of cell surfaces. Both HA and YHWYGYTPQNVI anchored on HLPR were responsible for targeting CD44 and EGFR overexpressed on the tumor cell surfaces, respectively. HLPR was relatively stable in the blood circulation and reached the tumor tissue in vivo through passive and active targeting. Then HLPR entered tumor cells mainly through EGFR-mediated pathway followed by the separation of HA from the remaining parts of nanocomplexes. The HA-uncoated complexes escaped the endosome through the membrane fusion function of DOPE and released cargoes (siRNA and peptide/siRNA) in the cytoplasm. HLPR significantly inhibited the growth of implanted subcutaneous liver tumors without toxicity.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,583 · see citing works
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · see citing works
Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer
Li, S., & Huang, L. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.06.022 · Cited by 487 · see citing works
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments
Tatiparti, K., Sau, S., Kashaw, S. K., & Iyer, A. K. (2017) · Nanomaterials · doi:10.3390/nano7040077 · Cited by 429 · see citing works
Li, Z., Zhao, R., Wu, X., Sun, Y., Yao, M., Li, J., Xu, Y., & Gu, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4058com · Cited by 420 · see citing works
Self-citationRecent Advances in Nanomaterials for Gene Delivery—A Review
Riley, M., & Vermerris, W. (2017) · Nanomaterials · doi:10.3390/nano7050094 · Cited by 354 · see citing works
Nano-based delivery of RNAi in cancer therapy
Xin, Y., Huang, M., Guo, W. W., Huang, Q., Zhang, L. Z., & Jiang, G. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0683-y · Cited by 296 · see citing works
Sheddable Ternary Nanoparticles for Tumor Acidity-Targeted siRNA Delivery
Yang, X., Du, J., Dou, S., Mao, C., Long, H., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn204240b · Cited by 284 · see citing works
Frontiers in cancer nanomedicine: directing mass transport through biological barriers
Mauro Ferrari, B. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2009.12.007 · Cited by 256 · see citing works
Chono, S., Li, S., Conwell, C. C., & Huang, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.006 · Cited by 237 · see citing works
The Role of the Helper Lipid on the DNA Transfection Efficiency of Lipopolyplex Formulations
Du, Z., Munye, M. M., Tagalakis, A. D., Manunta, M., & Hart, S. L. (2014) · Scientific Reports · doi:10.1038/srep07107 · Cited by 200 · see citing works
Self-citationKostarelos, K., & Miller, A. D. (2005) · Chemical Society Reviews · doi:10.1039/b307062j · Cited by 170 · see citing works
Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems
Kondo, E., Saito, K., Tashiro, Y., et al. (2012) · Nature Communications · doi:10.1038/ncomms1952 · Cited by 155 · see citing works
Kinoshita, R., Ishima, Y., Chuang, V. T. G., Nakamura, H., Fang, J. Q., Watanabe, H., Shimizu, T., Okuhira, K., Ishida, T., Maeda, H., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.06.021 · Cited by 146 · see citing works
Kim, I., Kang, Y., Lee, D. S., et al. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.07.005 · Cited by 144 · see citing works
Marina–García, N., Franchi, L., Kim, Y., Hu, Y., Smith, D. E., Boons, G., & Núñez, G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802197 · Cited by 133 · see citing works
Nanocarriers in Gene Therapy: A Review
Xu, H., Li, Z., & Jin, S. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2044 · Cited by 106 · see citing works
Hwang, D. W., Kim, H. Y., Li, F., Park, J. Y., Kim, D.-H., Park, J. H., Han, H. S., Byun, J. W., Lee, Y., Jeong, J. M., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.028 · Cited by 99 · see citing works
Liang, X., Shi, B., Wang, K., Fan, M., Jiao, D., Ao, J., Song, N., Wang, C., Gu, J., & Li, Z. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.015 · Cited by 89 · see citing works
Liu, L., Zheng, M., Librizzi, D., Renette, T., Merkel, O. M., & Kissel, T. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00575 · Cited by 88 · see citing works
Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery
Tagalakis, A. D., Lee, D. D. H., Bienemann, A. S., Zhou, H., Munye, M. M., Saraiva, L., McCarthy, D., Du, Z., Vink, C. A., Maeshima, R., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.06.003 · Cited by 85 · see citing works
Self-citationReceptor-targeted liposome-peptide nanocomplexes for siRNA delivery
Tagalakis, A. D., He, L., Saraiva, L., Gustafsson, K. T., & Hart, S. L. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.022 · Cited by 84 · see citing works
Self-citationWang, Y., Shi, K., Zhang, L., Hu, G., Wan, J., Tang, J., Yin, S., Duan, J., Qin, M., Wang, N., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1162930 · Cited by 84 · see citing works
Roberts, C. M., Shahin, S. A., Wen, W. X., et al. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.11.010 · Cited by 82 · see citing works
Bachar, G. Y., Cohen, K., Hod, R., Feinmesser, R., Mizrachi, A., Shpitzer, T., Katz, O., & Peer, D. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.040 · Cited by 73 · see citing works
Yang, F., Huang, W., Li, Y., Liu, S., Jin, M., Wang, Y., Jia, L., & Gao, Z. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.047 · Cited by 68 · see citing works
Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration
Tagalakis, A. D., Grosse, S. M., Meng, Q., Mustapa, M. F. M., Kwok, A., Salehi, S. E., Tabor, A. B., Hailes, H. C., & Hart, S. L. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.037 · Cited by 52 · see citing works
Self-citationEGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer
Mondal, G., Kumar, V., Shukla, S. K., Singh, P. K., & Mahato, R. I. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b01419 · Cited by 51 · see citing works
Jin, W., Wang, Q., Wu, M., Li, Y., Tang, G., Yuan, P., & Chu, P. K.-H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.03.020 · Cited by 43 · see citing works
Self-citationBiophysical Characterization of an Integrin-Targeted Lipopolyplex Gene Delivery Vector
Mustapa, M. F. M., Bell, P. C., Hurley, C. A., et al. (2007) · Biochemistry · doi:10.1021/bi701014y · Cited by 36 · see citing works
Cellular Uptake Mechanisms of Novel Anionic siRNA Lipoplexes
Kapoor, M., & Burgess, D. J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0952-9 · Cited by 32 · see citing works
Tagalakis, A. D., Maeshima, R., Yu‐Wai‐Man, C., Meng, J., Syed, F., Wu, L., Aldossary, A. M., McCarthy, D., Moghimi, S. M., & Hart, S. L. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.01.048 · Cited by 30 · see citing works
Self-citationDobiasch, S., Szanyi, S., Kjaev, A., et al. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0236-3 · Cited by 24 · see citing works
Zhang, M., Li, C., Fang, B., Yao, M., Ren, Q., Zhang, L., & Zhao, Y. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/25/255102 · Cited by 22 · see citing works
Chk2 Phosphorylation of Survivin-ΔEx3 Contributes to a DNA Damage–Sensing Checkpoint in Cancer
Lopergolo, A., Tavecchio, M., Lisanti, S., Ghosh, J. C., Dohi, T., Faversani, A., Vaira, V., Bòsari, S., Tanigawa, N., Delia, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4035 · Cited by 17 · see citing works
Xie, F., Zhang, L., Peng, J., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00709 · Cited by 14 · see citing works
Self-citationTagalakis, A. D., Castellaro, S., Zhou, H., Bienemann, A. S., Munye, M. M., McCarthy, D., White, E., & Hart, S. L. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s78935 · Cited by 13 · see citing works
Self-citationZhang, L., Li, Z., Sun, F., et al. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s115381 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98 · see citing works
“Dual targeting approaches with EGFR and CD44 are also effective for enhancing EPR-based drug delivery, which may decrease the uncertainty of a single targeting strategy [54,55].”
Background
- Authors
- Liang, Y., Peng, J., Li, N., Yu-Wai-Man, C., Wang, Q., Xu, Y., Wang, H., Tagalakis, A. D., & Du, Z.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Edge Hill University (GB)
- Corresponding author
- Wang, Hongxia
- Du, Zixiu
- Venue
- Nanomedicine Nanotechnology Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 15
- Issue
- 1
- Pages
- 208-217
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W2897401086
- Cited by
- 30
- References
- 38
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 4
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Nanomedicine Nanotechnology Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- Edge Hill University (submittedVersion)
- Edge Hill University Research Information Repository (Edge Hill University) (submittedVersion, cc-by-nc-nd)
- Funders
- National Natural Science Foundation of China (81690262)
- Engineering and Medical Cooperation Projects of Shanghai Jiao Tong University (YG2016MS22)
- Minhang “Production-Study-Research” Project in Shanghai (2016MH229)
- Development Fund for Shanghai Talents (2017111)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- siRNA delivery, nanoparticles, CD44 targeting, EGFR targeting, dual targeting, hyaluronic acid coating, peptide ligands, tumor targeting, endosomal escape, membrane fusion, liver tumors, cancer therapy
- MeSH terms
- Animals, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tumor Cells, Cultured, Drug Delivery Systems, Apoptosis, Hyaluronan Receptors, Xenograft Model Antitumor Assays, RNA, Small Interfering, Cell Proliferation, Mice, Nanoparticles, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review